232 related articles for article (PubMed ID: 32570201)
1. Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study.
Elliott J; DeJean D; Potter BK; Coyle D; Clifford T; McCoy B; Wells GA
Epilepsy Behav; 2020 Oct; 111():107120. PubMed ID: 32570201
[TBL] [Abstract][Full Text] [Related]
2. Neurologists' perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: A qualitative interview study.
Elliott J; DeJean D; Potter BK; Coyle D; Clifford T; McCoy B; Wells GA
Seizure; 2020 May; 78():118-126. PubMed ID: 32361185
[TBL] [Abstract][Full Text] [Related]
3. Family attitudes about and experiences with medical cannabis in children with cancer or epilepsy: an exploratory qualitative study.
Gibbard M; Mount D; Rassekh SR; Siden HH
CMAJ Open; 2021; 9(2):E563-E569. PubMed ID: 34021014
[TBL] [Abstract][Full Text] [Related]
4. An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use.
Suraev AS; Todd L; Bowen MT; Allsop DJ; McGregor IS; Ireland C; Lintzeris N
Epilepsy Behav; 2017 May; 70(Pt B):334-340. PubMed ID: 28238865
[TBL] [Abstract][Full Text] [Related]
5. Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.
Elliott J; van Katwyk S; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
Pharmacoeconomics; 2019 Oct; 37(10):1261-1276. PubMed ID: 31201643
[TBL] [Abstract][Full Text] [Related]
6. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
Tzadok M; Uliel-Siboni S; Linder I; Kramer U; Epstein O; Menascu S; Nissenkorn A; Yosef OB; Hyman E; Granot D; Dor M; Lerman-Sagie T; Ben-Zeev B
Seizure; 2016 Feb; 35():41-4. PubMed ID: 26800377
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
Hausman-Kedem M; Menascu S; Kramer U
Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131
[TBL] [Abstract][Full Text] [Related]
8. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
9. Medical cannabis: A needs analysis for people with epilepsy.
Kerai A; Sim TF; Emmerton L
Complement Ther Clin Pract; 2018 Nov; 33():43-48. PubMed ID: 30396625
[TBL] [Abstract][Full Text] [Related]
10. Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada.
Capler R; Walsh Z; Crosby K; Belle-Isle L; Holtzman S; Lucas P; Callaway R
Int J Drug Policy; 2017 Sep; 47():1-8. PubMed ID: 28667878
[TBL] [Abstract][Full Text] [Related]
11. Parent use of cannabis for intractable pediatric epilepsy: Everyday empiricism and the boundaries of scientific medicine.
Sobo EJ
Soc Sci Med; 2017 Oct; 190():190-198. PubMed ID: 28865255
[TBL] [Abstract][Full Text] [Related]
12. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
Porter BE; Jacobson C
Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of epileptic surgery compared with medical treatment in children with drug-resistant epilepsy.
Catchpool M; Dalziel K; Mahardya RTK; Harvey AS
Epilepsy Behav; 2019 Aug; 97():253-259. PubMed ID: 31254845
[TBL] [Abstract][Full Text] [Related]
14. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
Press CA; Knupp KG; Chapman KE
Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations.
Elliott J; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
Syst Rev; 2019 Mar; 8(1):75. PubMed ID: 30917869
[TBL] [Abstract][Full Text] [Related]
16. Clinician views on and ethics priorities for authorizing medical cannabis in the care of children and youth in Canada: a qualitative study.
Gunning M; Rotenberg AD; Kelly LE; Crooks B; Oberoi S; Rapoport AL; Rassekh SR; Illes J
CMAJ Open; 2022; 10(1):E196-E202. PubMed ID: 35292477
[TBL] [Abstract][Full Text] [Related]
17. Parents' experiences using medical cannabis for their child.
Ryan JE; Smeltzer SC; Sharts-Hopko NC
Nurs Outlook; 2020; 68(3):337-344. PubMed ID: 32334826
[TBL] [Abstract][Full Text] [Related]
18. Family income and the impact of a children's health insurance program on reported need for health services and unmet health need.
Feinberg E; Swartz K; Zaslavsky A; Gardner J; Walker DK
Pediatrics; 2002 Feb; 109(2):E29. PubMed ID: 11826239
[TBL] [Abstract][Full Text] [Related]
19. Petition against "cruel" and "ridiculous" guidance on access to medicinal cannabis attracts 400 000 signatures.
Dyer C
BMJ; 2018 Nov; 363():k4833. PubMed ID: 30442640
[No Abstract] [Full Text] [Related]
20. Cannabis Treatment in Children with Epilepsy: Practices of Canadian Neurologists.
DeGasperis SM; Webster R; Pohl D
Can J Neurol Sci; 2020 Jul; 47(4):511-518. PubMed ID: 32127067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
